The U.S. President said that Big Pharma would either voluntarily abide by this principle or the federal government will use its power to ensure the U.S. pays the same price as other countries.
Global pharmaceutical company Merck (NYSE:MRK) reported Q1 CY2025 results exceeding the market’s revenue expectations, but sales fell by 1.6% year on year to $15.53 billion. The company expects the full year’s revenue to be around $64.85 billion, close to analysts’ estimates. Its non-GAAP profit of $2.22 per share was 4% above analysts’ consensus estimates.
What Happened: On Sunday, President Donald Trump announced on Truth Social that he plans to sign what he called the "most consequential executive order" in U.S. history, aimed at lowering prescription drug prices.
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns -
over the past six months, healthcare stocks have collectively shed 13.3%. This performance was worse than the S&P 500’s 5.8% fall.
Pharma ETFs closely watched as Trump's drug policies stir market volatility. Funds offer sector exposure but differ in risk levels and growth potential.
Marjorie Taylor Greene disclosed buying more than 50 stocks in early May. A look at the list and why the congresswoman's past trades have drawn red flags.
Biopharma stocks rally along with many of our SMID cap trades. The market situation with pharmaceuticals is even more complicated because we started off with legislation (the IRA) trying to curb rising drug and healthcare costs.
